Immune escape and immunotherapy of acute myeloid leukemia.
Ontology highlight
ABSTRACT: In spite of the recent approval of new promising targeted therapies, the clinical outcome of patients with acute myeloid leukemia (AML) remains suboptimal, prompting the search for additional and synergistic therapeutic rationales. It is increasingly evident that the bone marrow immune environment of AML patients is profoundly altered, contributing to the severity of the disease but also providing several windows of opportunity to prompt or rewire a proficient antitumor immune surveillance. In this Review, we present current evidence on immune defects in AML, discuss the challenges with selective targeting of AML cells, and summarize the clinical results and immunologic insights from studies that are testing the latest immunotherapy approaches to specifically target AML cells (antibodies,
SUBMITTER: Vago L
PROVIDER: S-EPMC7108895 | biostudies-literature | 2020 Apr
REPOSITORIES: biostudies-literature
ACCESS DATA